Aseptic Abscess Syndrome
Conditions
Keywords
Aseptic abscess syndrome, Comparative Study, Pathophysiology
Brief summary
Aseptic abscess syndrome (AA) is a rare entity characterized by the occurrence of deep abscesses with no germ found. Antibiotic therapy is ineffective and they are sensitive to anti-inflammatory treatment with corticosteroids. Gut microbiota is important for the development of the immune system. In Crohn's disease which is frequently associated with AA syndrome, dysbiosis is found but could also be involved in the immune response at a distance from the gut. Stool, blood, saliva and urine samples will be taken from the patients included and their controls in the centers where they are followed. These biological samples will be transported to Clermont Ferrand using the same procedure (transporter and dry ice) where the following analyses will be performed: microbiota on stool and saliva, short chain fatty acids on stool and lymphocyte study on blood.
Detailed description
* Included patients will be adult patients meeting the diagnostic criteria for aseptic abscess syndrome described by André et al. * Controls will be adults without aseptic abscess syndrome living in the same environment as the patients, whether related to the patient or not. Patients and controls must be able to provide informed consent and be affiliated with the French Social Security system.
Interventions
OTHERBiological sample collection
All patients and their controls will be asked to provide a urine, stool, saliva and blood sample during a follow-up visit. Patients will not be specifically asked to take these samples, they will be taken during a follow-up visit, during which these samples are usually already taken.
Sponsors
University Hospital, Clermont-Ferrand
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Intervention model description
All patients and their controls will have a sample of urine, stool, saliva and blood taken during a follow-up visit. Patients will not be specifically asked to take these samples, they will be taken during a follow-up visit, during which these samples are usually already taken.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* For cases: adult patients meeting the diagnostic criteria for aseptic abscess syndrome described by André et al: * Deep abscesses on radiological examination with neutrophilic features proven by pathological analysis of a surgical specimen or biopsy when performed * Negative blood cultures, negative serological tests for bacteria, including always Yersinia enterocolitica, and, during surgery or aspiration, sterile pus (with standard cultures, BAAR and fungal tests) Failure of antibiotic therapy, when prescribed, after at least 2 weeks for conventional antibiotic therapy and at least 3 months for anti-tuberculosis treatment * Rapid clinical improvement the day after the prescription of corticosteroids (at least 1/2 mg/kg prednisone or equivalent) followed by radiological improvement after 1 month of corticosteroids, sometimes in association with immunosuppressive treatments. For controls: adult person living in the same environment as the case to which it is matched. Adult person living in the same household or near the patient. For cases and controls: * Ability to provide informed consent. * Membership in the Social Security system.
Exclusion criteria
* Pregnant women. Incapable patients Patients deprived of liberty Antibiotic therapy administered within 6 weeks prior to inclusion.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Gut microbiota profiling (diversity) of patients with aseptic abscess syndrome and matched healthy controls | day 1 | 16S rRNA gene sequencing technique and illumina MiSeq platform to investigate the difference of gut microbiota composition between patients with aseptic abscess syndrome and matched healthy controls. |
| Gut microbiota profiling (composition) of patients with aseptic abscess syndrome and matched healthy controls | day 1 | 16S rRNA gene sequencing technique and illumina MiSeq platform to investigate the difference of gut microbiota diversity between patients with aseptic abscess syndrome and matched healthy controls. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Th17/Treg Lymphocytes phenotyping | day 1 | Th17/Treg Lymphocytes phenotyping of patients with aseptic abscesses compared to matched healthy controls. |
| Salivary microbiota profiling (composition) of patients with aseptic abscess syndrome and matched healthy controls | day 1 | 16S rRNA gene sequencing technique and illumina MiSeq platform to investigate the difference of salivary microbiota composition between patients with aseptic abscess syndrome and matched healthy controls. |
| Salivary microbiota profiling (diversity) of patients with aseptic abscess syndrome and matched healthy controls | day 1 | 16S rRNA gene sequencing technique and illumina MiSeq platform to investigate the difference of salivary microbiota diversity between patients with aseptic abscess syndrome and matched healthy controls. |
Countries
France
Contacts
Primary ContactLise Laclautre, PharmD
Backup ContactTrefond Ludovic, MD
Outcome results
None listed